Corneal Epithelial And Refractive Alterations Associated With Belantamab Mafodotin Treatment In Patients Diagnosed With Refractory Multiple Myeloma
Published 2025 - 43rd Congress of the ESCRS
Reference: PP20.01 | Type: Poster | DOI: 10.82333/p7dr-ss69
Authors: Jhon Jarold Reyes Muñoz* 1 , Ines Marinho de Matos Morgado 1
1Oftalmologia,Hospital General Universitario de Castellon,Castellon,Spain
Purpose
The aim of this study was to investigate the presence of corneal epithelial microcysts (MEC) and document associated refractive changes on the corneal surface in patients with refractory multiple myeloma treated with Belantamab Mafodotin, a humanized monoclonal antibody conjugated with a cytotoxic agent specific to B cells in myeloma.
Setting
This study was conducted at the General University Hospital of Castellon, Spain, between January 2023 and December 2023. It included 12 eyes of 6 adult patients on belantamab mafodotin, recruited from the hospital's ophthalmology department. All participants were followed up for 12 months.
Methods
A retrospective study was conducted using clinical records of 12 eyes from 6 patients with keratopathy associated with belantamab mafodotin. The study period ranged from January 1st in 2023 to January 1st in 2024. Follow up was performed during 1 year. Drug-induced alterations were evaluated at 3, 6 and 12 months after treatment initiation. Collected data included age, gender, visual acuity, biomicroscopic examination, automated refraction, tomography and topography measurements. Statistical significance was calculated using SPSS Base 14.0 software.
Results
The study analyzed the correlation between the location of MEC and refractive changes in the 12 eyes studied. A significant association was found between the peripheral location of microcysts and the development of hypermetropic changes (p < 0.05). On the other hand, myopic refractive alterations were significantly associated with the presence of central and paracentral epithelial microcysts.
Conclusions
The development of MEC occurred in the early months of treatment and showed a statistically significant association with hypermetropic changes. In contrast, those located at the paracentral and central levels, which appeared later in the treatment, led to an increase in central corneal thickness and, consequently, myopic refractive changes.